Table 1.
Baseline characteristics of patients with second haemoglobin measurement in first six months of ART initiation
| Characteristic | All patients (n = 3105) | Patients with early severe anaemia (n = 109) |
|---|---|---|
| Gender | ||
| Female | 2065 (67%) | 80 (73%) |
| Male | 1040 (23%) | 29 (26%) |
| Age (yrs) median (IQR) | 36 (31,42) | 37 (30,41) |
| BMI (kg/m2) median | ||
| (IQR) | 20 (18,23) | 18 (17,22) |
| WHO stage | ||
| I-II | 937 (30%) | 25 (23%) |
| III- IV | 2168 (70%) | 84 (76%) |
| CD4 T cell count, | ||
| Median (IQR) | 101 (33, 173) | 65 (21,144) |
| 200+ | 426 (14%) | 12 (11%) |
| 50-199 | 1589 (51%) | 47 (43%) |
| <50 | 942 (30%) | 44 (40%) |
| Missing | 148 (5%) | 6 (6%) |
| HB g/dL | ||
| ≥8 | 2959 | 79 |
| <8 | 146 | 30 |
| MCV, median (IQR) | 84 (79,90) | 79 (74,86) |
| ≥80fL | 2225 | 54 |
| <80fL | 880 | 55 |
| TB | ||
| No | 3035 (98%) | 93 (85%) |
| Yes | 70 (2%) | 16 (15%) |
| Regimen | ||
| d4T-containing | 1965 | 65 |
| AZT-containing | 1140 | 44 |
BMI = body mass index, HB = hemoglobin, MCV = mean corpuscular volume, IQR = interquartile range, TB = tuberculosis, ART = antiretroviral therapy, d4T = stavudine, AZT = zidovudine, OR = odds ratio